GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jaguar Health Inc (NAS:JAGX) » Definitions » E10

JAGX (Jaguar Health) E10 : $-2,614,940.00 (As of Sep. 2024)


View and export this data going back to 2015. Start your Free Trial

What is Jaguar Health E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Jaguar Health's adjusted earnings per share data for the three months ended in Sep. 2024 was $-1.050. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-2,614,940.00 for the trailing ten years ended in Sep. 2024.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2024-12-15), Jaguar Health's current stock price is $0.9693. Jaguar Health's E10 for the quarter that ended in Sep. 2024 was $-2,614,940.00. Jaguar Health's Shiller PE Ratio of today is .


Jaguar Health E10 Historical Data

The historical data trend for Jaguar Health's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jaguar Health E10 Chart

Jaguar Health Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -3,461,340.00

Jaguar Health Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,562,170.00 -3,461,340.00 -3,253,890.00 -2,989,830.00 -2,614,940.00

Competitive Comparison of Jaguar Health's E10

For the Biotechnology subindustry, Jaguar Health's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jaguar Health's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Jaguar Health's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Jaguar Health's Shiller PE Ratio falls into.



Jaguar Health E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Jaguar Health's adjusted earnings per share data for the three months ended in Sep. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-1.05/133.0289*133.0289
=-1.050

Current CPI (Sep. 2024) = 133.0289.

Jaguar Health Quarterly Data

per share eps CPI Adj_EPS
201412 -2,149,910.000 99.070 -2,886,858.065
201503 -4,124,470.000 99.621 -5,507,605.389
201506 -159,470.000 100.684 -210,700.208
201509 -87,078.600 100.392 -115,387.960
201512 -121,495.000 99.792 -161,959.690
201603 -94,862.000 100.470 -125,603.038
201606 -81,277.200 101.688 -106,327.255
201609 -68,309.800 101.861 -89,211.549
201612 -3,676,610.000 101.863 -4,801,516.002
201703 -4,715,360.000 102.862 -6,098,247.499
201706 -1,805,640.000 103.349 -2,324,183.791
201709 475,984.000 104.136 608,049.773
201712 -1,554,420.000 104.011 -1,988,083.798
201803 -393,626.000 105.290 -497,330.064
201806 -508,952.000 106.317 -636,826.209
201809 -341,020.000 106.507 -425,940.485
201812 -342,908.000 105.998 -430,354.507
201903 -116,958.000 107.251 -145,069.665
201906 -118,589.000 108.070 -145,977.951
201909 -16,595.200 108.329 -20,378.966
201912 -7,528.640 108.420 -9,237.463
202003 -7,560.010 108.902 -9,234.949
202006 -5,940.010 108.767 -7,264.987
202009 -2,790.000 109.815 -3,379.784
202012 -1,345.490 109.897 -1,628.701
202103 -1,260.000 111.754 -1,499.864
202106 -1,395.000 114.631 -1,618.887
202109 -1,215.000 115.734 -1,396.562
202112 -1,332.060 117.630 -1,506.446
202203 -1,386.000 121.301 -1,520.004
202206 -526.200 125.017 -559.923
202209 -529.800 125.227 -562.810
202212 -208.452 125.222 -221.448
202303 -143.400 127.348 -149.797
202306 -41.350 128.729 -42.731
202309 -22.500 129.860 -23.049
202312 -7.495 129.419 -7.704
202403 -3.600 131.776 -3.634
202406 -4.040 132.554 -4.054
202409 -1.050 133.029 -1.050

Add all the adjusted EPS together and divide 10 will get our e10.


Jaguar Health  (NAS:JAGX) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Jaguar Health E10 Related Terms

Thank you for viewing the detailed overview of Jaguar Health's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


Jaguar Health Business Description

Traded in Other Exchanges
N/A
Address
200 Pine Street, Suite 400, San Francisco, CA, USA, 94104
Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.
Executives
Anula Jayasuriya director 5150 EL CAMINO REAL, SUITE #A-32, LOS ALTOS CA 94022
Pravin R Chaturvedi officer: Chief Scientific Officer C/O JAGUAR HEALTH INC., 200 PINE STREET, SUITE 400, SAN FRANCISCO CA 94104
Lisa A Conte director, officer: CEO & President 213 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Carol R. Lizak officer: Chief Accounting Officer 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
James J Bochnowski director C/O DELPHI VENTURES, 160 BOVET RD, SUITE 408, SAN MATEO CA 94402
Jonathan S. Wolin officer: Chief of Staff, CCO & GC 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Jonathan B. Siegel director C/O KINGDON CAPITAL MANAGEMENT, L.L.C., 152 WEST 57TH STREET, 50TH FLOOR, NEW YORK NY 10019
Bryan Ezralow 1994 Trust Dated December 22, 1994 10 percent owner 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302
Bryan Ezralow 10 percent owner THE EZRALOW CO, LLC, 23622 CALABASAS ROAD, SUITE 200, CALABASAS CA 91302-1549
Nantucket Investments Ltd 10 percent owner PO BOX 282, REGENCY COURT, GLATEGNY ESPLANADE, ST PETER PORT Y7 GY1 3RH
Jonathan M Glaser 10 percent owner 11601 WILSHIRE BLVD., SUITE 2180, LOS ANGELES CA 90025
Murray David Macnaughtan director C/O JAGUAR HEALTH, INC., 201 MISSION STREET, SUITE 2375, SAN FRANCISCO CA 94105
Greg J Divis director 10-1 BLANCHARDSTOWN CORPORATE PARK, BALLYCOOLIN, DUBLIN L2 15
Jeffery C. Johnson director C/O SAGARD CAPITAL PARTNERS, L.P., 280 PARK AVENUE, 3F WEST, STAMFORD CT 06901
Sagard Capital Partners, L.p. 10 percent owner 280 PARK AVENUE, 3RD FLOOR WEST, NEW YORK NY 10017